Study Aims and Results
Studies on the aged population infected with the hepatitis C virus are lacking. The current study estimated the number of life years and quality-adjusted life years (disease burden, medical burden, future medical intervention) gained with the treatment of Harvoni (sofosbuvir plus ledipasvir) in treatment naïve patients. The data was extracted from published studies and expert opinion. The Markov model was used to estimate HCV disease progression toward advanced liver disease. The Markov model is a standardized model that estimates a possible eventual outcome (long-term disease outcome) based on predetermined factors (current disease state, cure).
The Markov model predicted that life years and the quality adjusted life years “gradually decreased with advancing age but the rate of decline was slower with more advanced fibrosis stage.” In those with F1, F2, F3 life years gained was below 6 months if treated by 55, 65 or 70 years old. The authors concluded that “the quality of life years gained for treated over untreated elderly were reasonably high even for those treated at early fibrosis state.” The authors also concluded that there is significant life expectancy benefit to HCV treatment in pateints up to age 75 with advanced stage fibrosis.”
There is a significant life expectancy and monetary benefit to HCV treatment in patients up to age 75 with advanced-stage fibrosis. HCV treatment is now easier to tolerate and the cure rates are very high. We should be testing every ‘Baby Boomer’ (and perhaps those even born 5 to 10 years earlier than ‘Baby Boomers’) and those at-risk for hepatitis C and treating everyone infected with hepatitis C. This would decrease the disease progression, the medical burden and importantly increase the quality of life for everyone with hepatitis C including those who are up to and beyond age 75 year old.
SOURCE: PLoS One. 2016 Jul 13;11(7):e0157832. doi: 10.1371/journal.pone.0157832. eCollection 2016.Share This Page